TxCell presents final positive results of the phase I/II clinical trial with antigen-specific Treg cells in Crohn’s disease
TxCell SA announced the presentation of final positive results of the phase I/II study in Crohn’s disease (CATS-1) with its leading product candidate, OvaSave(R). The results of this study, performed on 20 patients, were announced at the United European gastroenterology Week (UEGW) in Stockholm, held October 22 to 26.
The CATS-1 study was a first in man, open label, multicenter phase I/II study in France to evaluate the tolerability and efficacy of OvaSave(R), an antigen-specific regulatory T cell-based immunotherapy. The CATS-1 study was for patients with severe chronic active Crohn’s disease, who had failed current treatments, including multiple biologics. Crohn’s disease is a chronic, often disabling disorder with a significant unmet medical need as existing treatments still do not provide satisfactory relief to patients.
The results presented at the United European Gastroenterology Week show that OvaSave(R) is well tolerated. The results also showed a positive efficacy signal, with 40 per cent of the patients positively responding five weeks after treatment in the overall population group. This positive effect was particularly relevant in the best dose group with 75 per cent of patients responding and 38 per cent remitting five weeks after treatment.
The present evidence has led TxCell to plan the continuation of the clinical development of OvaSave(R) for the treatment of Crohn’s disease with a controlled phase II study.
“The results indicate the potential of our antigen-specific Treg cell approach for the management of multiple chronic inflammatory diseases,” said François Meyer, chief executive officer of TxCell. “160,000 people are affected by severe Crohn’s disease in Europe and US*. Confirmation of these positive results will provide a new hope for patients in a refractory state of the disease.”
“The open label evidence on the tolerance profile and the dose-related significant clinical effect are very encouraging,” said Miguel Forte, chief medical officer of TxCell. “This will be the basis for the next steps in the clinical development plan of OvaSave(R) in Crohn’s disease. The company will initiate a phase II study in the same patient population.”
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
